Conatus Pharmaceuticals Inc (CNAT)

2.07
NASDAQ : Health Care
Prev Close 2.07
Day Low/High 0.00 / 0.00
52 Wk Low/High 1.40 / 5.44
Avg Volume 444.40K
Exchange NASDAQ
Shares Outstanding 22.09M
Market Cap 46.38M
EPS -1.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Conatus Pharmaceuticals (CNAT) Stock Surges, Liver Drug Could Treat Zika

Conatus Pharmaceuticals (CNAT) Stock Surges, Liver Drug Could Treat Zika

Conatus Pharmaceuticals' (CNAT) patented liver drug emricasan has been identified as a promising treatment for the Zika virus.

Exalenz Bioscience Announces Collaboration with Conatus Pharmaceuticals to Use BreathID® to Monitor Patients with Cirrhosis Associated with NASH

Exalenz Bioscience Announces Collaboration with Conatus Pharmaceuticals to Use BreathID® to Monitor Patients with Cirrhosis Associated with NASH

Company's non-invasive BreathID® System to be used to quantitate liver function in Conatus Phase IIb clinical trial of emricasan; Currently no approved non-invasive diagnostic tests exist to diagnose or monitor NASH which affects 2-5% of the US population

Conatus Pharmaceuticals Reports First Quarter 2016 Financial Results And Program Updates

Conatus Pharmaceuticals Reports First Quarter 2016 Financial Results And Program Updates

Conference Call and Webcast Presentation at 8:00 a.m. ET Today

Conatus Poster At EASL Meeting Today Addresses Safety Of Caspase Inhibition In Cancer Treatment

Conatus Poster At EASL Meeting Today Addresses Safety Of Caspase Inhibition In Cancer Treatment

Late Breaker Oral Presentation Tomorrow to Detail Phase 2 Liver Cirrhosis Trial 3-month Results

FDA Grants Conatus Fast Track Designation For Development Of Emricasan In NASH Cirrhosis

FDA Grants Conatus Fast Track Designation For Development Of Emricasan In NASH Cirrhosis

Focusing on Initial Registration in NASH Cirrhosis With Parallel Development in NASH Fibrosis

Conatus Initiates Phase 2b ENCORE-NF Clinical Trial Of Emricasan In Patients With NASH Fibrosis

Conatus Initiates Phase 2b ENCORE-NF Clinical Trial Of Emricasan In Patients With NASH Fibrosis

Adding Long-term Safety Data to Support Initial Registration of Emricasan in Cirrhosis

Conatus Pharmaceuticals (CNAT) Stock Soars on Positive Liver Drug Trial Results

Conatus Pharmaceuticals (CNAT) Stock Soars on Positive Liver Drug Trial Results

Conatus Pharmaceuticals (CNAT) stock is increasing in mid-morning trading on Wednesday after the company said a Phase 2 trial of its liver drug showed positive results.